If your search is regorafenib buy stivarga, you are looking for Bayer's originator oral multikinase inhibitor, sold worldwide under the brand Stivarga (拜万戈 in Chinese). GLT supplies the China-sourced Stivarga (Regorafenib) 40mg tablets, an NMPA-approved and reimbursed treatment for metastatic colorectal cancer (mCRC), gastrointestinal stromal tumor (GIST) and hepatocellular carcinoma (HCC), at an indicative price of around $400 for a 28-tablet box.
What Is Stivarga (Regorafenib)?
Stivarga is the brand name for regorafenib, a small-molecule multikinase inhibitor developed and marketed by Bayer of Germany. Unlike a single-target therapy, regorafenib blocks multiple kinases involved in tumor growth, blood-vessel formation and the tumor microenvironment, which is why it works across several different advanced cancers. It was first approved by the U.S. FDA in 2012, and in China it was approved in 2017 with the Chinese brand name 拜万戈 (Stivarga) under approval number 国药准字HJ20171300.
Regorafenib is an oral tablet taken at home, not an infusion, which makes it a practical later-line option for patients managing advanced disease. The tablets are light-pink, oval and film-coated, debossed with "BAYER" on one side and "40" on the other. You can review the full official prescribing information on the DailyMed entry for Stivarga and on the Stivarga product site. This guide covers what Stivarga is, the three cancers it treats, its 40 mg dosing, current pricing and how to source it safely.
How Does Regorafenib Work?
Regorafenib is called a multikinase inhibitor because it blocks several signaling proteins at once rather than a single target. Among the kinases it inhibits are VEGFR and TIE-2 (which drive the growth of blood vessels that feed tumors), RAF (part of the cell-proliferation pathway), and KIT and RET (implicated in specific tumor types such as GIST). By hitting this broad set of targets, regorafenib both slows tumor growth and disrupts the tumor's blood supply, which is why a single oral tablet can be useful across colorectal, stromal and liver cancers that have different underlying drivers.
What Is Stivarga Used For? Three Approved Indications
Stivarga is approved for three advanced solid tumors, always in patients whose disease has progressed after earlier lines of treatment:
- Metastatic colorectal cancer (mCRC) — for patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.
- Gastrointestinal stromal tumor (GIST) — for locally advanced, unresectable or metastatic disease previously treated with imatinib and sunitinib.
- Hepatocellular carcinoma (HCC) — for patients previously treated with sorafenib.
In China, Stivarga is reimbursed under the national medical insurance list for these later-line settings, which has meaningfully improved access. The China label and the US label cover the same three indications, so the medicine is interchangeable in clinical terms; the difference is simply which regional packaging and reimbursement pathway applies.
Stivarga 40mg: Dosage and How It Is Taken
Stivarga is supplied as 40 mg tablets, with 28 tablets per bottle. The standard dose is 160 mg once daily — that is four 40 mg tablets taken together — for the first 21 days of each 28-day cycle, followed by a 7-day break. The tablets are taken whole with water after a low-fat meal, at the same time each day.
The dose can be reduced in 40 mg steps down to a minimum of 80 mg per day depending on how well a patient tolerates treatment, so the 40 mg tablet is the building block of every dose level. Because regorafenib carries a boxed warning for hepatotoxicity, liver function is monitored before starting and during treatment, and the dose may be interrupted or reduced if liver enzymes rise. Common side effects include hand-foot skin reaction, fatigue, diarrhea, hypertension, decreased appetite, mucositis and dysphonia — most of which are managed through dose adjustment rather than stopping therapy.
Side Effects and Safety Monitoring
Stivarga carries a boxed warning for hepatotoxicity — severe and sometimes fatal liver injury has occurred in clinical trials. Because of this, liver function tests (ALT, AST and bilirubin) are checked before treatment starts and monitored regularly throughout, with the dose interrupted or reduced if liver enzymes become elevated. The most common side effects (occurring in at least 20% of patients) include hand-foot skin reaction, fatigue, diarrhea, decreased appetite, hypertension, infection, dysphonia (voice changes), mucositis, weight loss and rash.
Several of these are manageable with supportive care and dose adjustment. Hand-foot skin reaction, the most frequent skin toxicity, is typically managed with moisturizers, pressure relief and, when needed, a temporary dose reduction. Blood pressure should be monitored because regorafenib can raise it, and treatment is withheld for severe or uncontrolled hypertension. Patients should also report any signs of infection, bleeding or new heart symptoms promptly. Because regorafenib can harm a developing fetus, effective contraception is advised during treatment and for two months after the final dose.
Stivarga Price: What to Expect
If your search is "stivarga price" or "buy stivarga," the key point is that the China-market originator is materially more affordable than Western list prices. After inclusion in China's national reimbursement program, the originator Stivarga retails in mainland China for roughly 2,600–2,700 RMB per 28-tablet box (about $360). GLT's indicative price for the China-sourced Stivarga 40mg is around $400 per box, with the exact figure confirmed at inquiry along with batch and expiry details.
For patients who want the German-origin presentation, GLT also lists the Bayer Germany Stivarga (Regorafenib) 40mg on a quote basis. Because Stivarga is a prescription cancer medicine, final pricing is always confirmed through the inquiry process rather than a fixed cart price.
For cost-sensitive patients, China also produces several approved generic regorafenib 40 mg formulations that are typically priced well below the originator. If the originator brand is not required, ask our team about the currently available generic alternatives and their sourcing details.
Where to Buy Regorafenib (Stivarga)
Stivarga is a prescription oncology medicine, so sourcing is handled through an inquiry process rather than a self-service checkout:
- Confirm the indication and that Stivarga is the right later-line option with your oncologist.
- Send your inquiry via WhatsApp or email with the strength (40 mg), pack size (28 tablets) and quantity you need.
- Our team verifies availability, batch and expiry, then arranges dispatch with appropriate handling.
For broader guidance on sourcing oncology medicines from China, see our China-sourced oncology medicines guide, and browse our other buying guides for related treatments.
What to Check Before You Buy Stivarga
Because regorafenib is a high-value oncology medicine, a few simple checks help ensure you receive a genuine, properly handled product rather than an unverified repack:
- Confirm the indication and line of therapy with your oncologist — Stivarga is used only after earlier lines of treatment have been tried, not as a first option.
- Verify the pack details: 40 mg strength, 28 tablets per bottle, plus the batch number and expiry date.
- Check storage and handling — regorafenib should be kept sealed, protected from light and stored at or below 25°C.
- Buy through a traceable channel that can provide batch documentation, rather than an unverified reseller.
GLT's inquiry process covers all of these points before dispatch, so you receive a product with confirmed origin, batch and expiry. Taking these steps protects both the quality of the medicine and your confidence in the supply chain.
Questions or ready to order? Contact us on WhatsApp +86 15234153837 or email [email protected].
Frequently Asked Questions
What is Stivarga used for?
Stivarga (regorafenib) is used to treat metastatic colorectal cancer, gastrointestinal stromal tumor (GIST) and hepatocellular carcinoma (HCC), in each case after the disease has progressed on earlier lines of therapy.
Is Stivarga the same as regorafenib?
Yes. Regorafenib is the active ingredient and Stivarga is Bayer's brand name for it. In China the brand is written 拜万戈 (Stivarga), and it is the same 40 mg oral tablet.
How is Stivarga dosed?
The standard dose is 160 mg (four 40 mg tablets) once daily for the first 21 days of each 28-day cycle, taken after a low-fat meal. The dose can be reduced in 40 mg steps based on tolerability.
How much does Stivarga cost?
GLT's indicative price for the China-sourced Stivarga 40mg is around $400 per 28-tablet box. The German-origin version is available on a quote basis. Contact us for a current quote.
Who makes Stivarga?
Stivarga is developed and marketed by Bayer AG of Germany. It was first approved by the US FDA in 2012 and by China's NMPA in 2017.
Do I need a prescription to buy regorafenib (Stivarga)?
Yes. Stivarga is a prescription oncology medicine. GLT's inquiry process includes verification before dispatch — contact us via WhatsApp or email, and our team will guide you through what is required.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Stivarga (regorafenib) is a prescription cancer medicine; always consult a qualified oncologist or healthcare professional about diagnosis, dosage and treatment. Prices are indicative and subject to confirmation at inquiry.